The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients with metastatic colorectal cancer (CRC) harboring the BRAF V600E mutation, as confirmed by an FDA-authorized test, according to the regulatory agency.
The approval covers Braftovi in combination with Erbitux (cetuximab) and fluorouracil-based chemotherapy. This follows the drug’s accelerated approval in 2024 for use with Erbitux and mFOLFOX6 in the same patient population. This U.S. FDA approval provides a new, evidence-based option for patients with a historically difficult-to-treat form of CRC, offering improved outcomes over standard chemotherapy regimens.
BREAKWATER trial shows significant benefits
The FDA approval is supported by results from the phase 3 BREAKWATER trial, a large, multicenter study in adults with previously untreated metastatic colorectal cancer carrying the BRAF V600E mutation. Patients were tested using an FDA-approved BRAF test to confirm their mutation status.
Glossary
mFOLFOX6 – A chemotherapy combination of multiple drugs given to treat colorectal cancer.
FOLFIRI – Another combination of chemotherapy drugs used for colorectal cancer treatment.
Progression-free survival (PFS) – The length of time a patient lives without the cancer getting worse after starting treatment.
Overall survival (OS) – The length of time a patient lives after starting treatment, regardless of whether the cancer grows or shrinks.
Objective response rate (ORR) – The percentage of patients whose tumors shrink or disappear after treatment.
In the main portion of the trial, 236 patients received Braftovi plus Erbitux and mFOLFOX6 chemotherapy, while 243 patients received standard chemotherapy. Patients taking the Braftovi combination experienced longer periods without cancer growth (median progression-free survival) at 12.8 months versus 7.1 months for standard chemotherapy.
Survival also improved, with patients on the Braftovi combination living 30.3 months compared with 15.1 months on standard treatment. The combination also produced a higher objective response rate, with more patients seeing their tumors shrink compared with chemotherapy alone: 61% versus 40%.
A second part of the study looked at Braftovi plus Erbitux with FOLFIRI chemotherapy compared with FOLFIRI alone. In this group, the combination treatment led to tumor shrinkage in 64% of patients, compared with 39% on FOLFIRI alone. These results show that combining Braftovi with Erbitux can improve outcomes across different chemotherapy regimens.
Background and clinical significance of the Braftovi combo
Colorectal cancer is among the leading causes of cancer-related death worldwide. Approximately 8% to 10% of metastatic CRC cases carry the BRAF V600E mutation, which is associated with aggressive disease and poor prognosis. Treatment options have historically been limited, particularly in patients whose tumors are resistant to standard chemotherapy.
Braftovi, a selective BRAF inhibitor, targets the V600E mutation directly. When combined with Erbitux, an EGFR inhibitor, and chemotherapy, the combination disrupts multiple growth pathways, enhancing tumor response. This combination marks an important advancement in precision medicine for CRC.
BREAKWATER trial methods and patient population
The BREAKWATER trial enrolled adult patients with previously untreated, BRAF V600E–positive metastatic CRC. Treatment continued until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up or death. The primary efficacy end points were progression-free survival and objective response rate, with overall survival as a key secondary end point.
The trial design included multiple experimental arms and a control arm using standard regimens, such as mFOLFOX6, FOLFOXIRI, or CAPOX, with or without Avastin (bevacizumab). This comprehensive design enabled direct comparison of targeted therapy combinations against standard care.
Additional findings and safety considerations
The prescribing information includes warnings and precautions for new primary malignancies, cardiomyopathy, hepatotoxicity, hemorrhage, uveitis, QT prolongation and embryo-fetal toxicity. The recommended dose is 300 milligrams of Braftovi orally once daily, combined with Erbitux and either mFOLFOX6 or FOLFIRI, continued until disease progression or unacceptable toxicity.
The traditional approval of Braftovi with Erbitux and chemotherapy provides a validated option for patients with BRAF V600E metastatic CRC. By combining targeted therapy with standard chemotherapy, the approach offers hope for improved survival in a population with historically limited treatment options.
References
- “FDA grants traditional approval to encorafenib for metastatic colorectal cancer with a BRAF V600E mutation,” by the U.S. Food and Drug Administration. News release; Feb. 24, 2026.
For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
